Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXEPT: XELIRI vs FOLFIRI in Metastatic Colorectal Cancer
NCT01996306Phase 3Completed
- Sponsor
- Epidemiological and Clinical Research Information Network
- Start
- Dec 2013
- Primary completion
- Nov 2017
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in colorectal cancer (metastatic) (mCRC), sponsored by Epidemiological and Clinical Research Information Network. Started Dec 2013; status: completed.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT01996306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01996306.